Abstract
Five independently evolved classes (α-, β-, γ-, δ-, ζ-) of carbonic anhydrases facilitate the reversible hydration of carbon dioxide to bicarbonate of which the α-class is the most extensively studied. Detailed inhibition studies of the α-class with the two main classes of inhibitors, sulfonamides and metal-complexing anions, revealed many inhibitors that are used as therapeutic agents to prevent and treat many diseases. Recent inhibitor studies of the archaeal β-class (Cab) and the γ-class (Cam) carbonic anhydrases show differences in inhibition response to sulfonamides and metal-complexing anions, when compared to the α-class carbonic anhydrases. In addition, inhibition between Cab and Cam differ. These inhibition patterns are consistent with the idea that although, α-, β-, and γ-class carbonic anhydrases participate in the same two-step isomechanism, diverse active site architecture among these classes predicts variations on the catalytic mechanism. These inhibitor studies of the archaeal β- and γ-class carbonic anhydrases give insight to new applications of current day carbonic anhydrase inhibitors, as well as direct research to develop new compounds that may be specific inhibitors of prokaryotic carbonic anhydrases.
Keywords: glutamine, Pisum sativum, bicarbonate, heterocyclic sulfonamides, Anion Inhibition
Current Topics in Medicinal Chemistry
Title: Inhibition of the Archaeal β-Class (Cab) and γ-Class (Cam) Carbonic Anhydrases
Volume: 7 Issue: 9
Author(s): Sabrina A. Zimmerman, James G. Ferry and Claudiu T. Supuran
Affiliation:
Keywords: glutamine, Pisum sativum, bicarbonate, heterocyclic sulfonamides, Anion Inhibition
Abstract: Five independently evolved classes (α-, β-, γ-, δ-, ζ-) of carbonic anhydrases facilitate the reversible hydration of carbon dioxide to bicarbonate of which the α-class is the most extensively studied. Detailed inhibition studies of the α-class with the two main classes of inhibitors, sulfonamides and metal-complexing anions, revealed many inhibitors that are used as therapeutic agents to prevent and treat many diseases. Recent inhibitor studies of the archaeal β-class (Cab) and the γ-class (Cam) carbonic anhydrases show differences in inhibition response to sulfonamides and metal-complexing anions, when compared to the α-class carbonic anhydrases. In addition, inhibition between Cab and Cam differ. These inhibition patterns are consistent with the idea that although, α-, β-, and γ-class carbonic anhydrases participate in the same two-step isomechanism, diverse active site architecture among these classes predicts variations on the catalytic mechanism. These inhibitor studies of the archaeal β- and γ-class carbonic anhydrases give insight to new applications of current day carbonic anhydrase inhibitors, as well as direct research to develop new compounds that may be specific inhibitors of prokaryotic carbonic anhydrases.
Export Options
About this article
Cite this article as:
Zimmerman A. Sabrina, Ferry G. James and Supuran T. Claudiu, Inhibition of the Archaeal β-Class (Cab) and γ-Class (Cam) Carbonic Anhydrases, Current Topics in Medicinal Chemistry 2007; 7 (9) . https://dx.doi.org/10.2174/156802607780636753
DOI https://dx.doi.org/10.2174/156802607780636753 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Exploring and Exploiting Gene Networks That Regulate Natural Products Biosynthesis in Actinobacteria
The Natural Products Journal The TB Structural Genomics Consortium: Providing a Structural Foundation for Drug Discovery
Current Drug Targets - Infectious Disorders Epidemiology of HIV in Iran
Current HIV Research Towards a Stratified Targeted Approach with Biologic Treatments in Rheumatoid Arthritis: Role of Synovial Pathobiology
Current Pharmaceutical Design Wzy-Dependent Bacterial Capsules as Potential Drug Targets
Current Drug Targets Studies on Chemistry, Spectroscopy and Antioxidant Activities of Chromium(III)-Hydrazide Complexes
Medicinal Chemistry Autophagy as a Potential Therapeutic Target in Breast Cancer Treatment
Current Cancer Drug Targets Preparation of Knockout Extract for Determination of Really Active Compound Using MAb
Current Drug Discovery Technologies Editorial (Thematic Issue: Role of Data and Methods in Chemoinformatics for Virtual Screening)
Combinatorial Chemistry & High Throughput Screening Recent Advancement in Predicting Subcellular Localization of Mycobacterial Protein with Machine Learning Methods
Medicinal Chemistry Drugs that Inhibit Mycolic Acid Biosynthesis in Mycobacterium tuberculosis - An Update
Medicinal Chemistry Reviews - Online (Discontinued) Synthesis, Antitrypanosomal and Antimycobacterial Activities of Coumarin N-acylhydrazonic Derivatives
Medicinal Chemistry Recent Advances in the Diagnosis and Therapy of Primary Adrenal Insufficiency
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents HIF-1α Deficiency Perturbs T and B Cell Functions
Current Pharmaceutical Design Design, Synthesis and Mode of Action of Some New 2-(4'-aminophenyl) benzothiazole Derivatives as Potent Antimicrobial Agents
Letters in Drug Design & Discovery Synthetic Peptides for the Immunodiagnosis of Human Diseases
Current Medicinal Chemistry Curcumin: A Dietary Phytochemical for Targeting the Phenotype and Function of Dendritic Cells
Current Medicinal Chemistry Acute Ischemic Cerebrovascular Events on Antiplatelet Therapy: What is the Optimal Prevention Strategy?
Current Pharmaceutical Design The Endoplasmic Reticulum Alpha-Glycosidases as Potential Targets for Virus Control
Current Protein & Peptide Science Vanadium Complexes with Hydrazone or Thiosemicarbazone Ligands as Potential Anti-Mycobacterium tuberculosis Agents
Current Clinical Pharmacology